对抗阿尔茨海默病的线粒体向:冬眠的经验教训
Christina F de Veij Mestdagh1,2,3, August B Smit1, Robert H Henning2
1Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.
Cells
|January 11, 2024
概括
研究阿尔茨海默病 (AD),这项研究探讨线粒体功能障碍,并提出了新的冬眠启发疗法. 准ATP和ROS通路可能会增强线粒体健康和突触功能,用于未来的AD治疗.
科学领域:
- 神经科学是一个神经科学.
- 线粒体生物学 线粒体生物学
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,没有有效的治疗方法.
- 线粒体功能障碍越来越多地与阿尔茨海默病的发病有关,导致突触缺陷和认知能力下降.
- 目前针对阿尔茨海默病的线粒体向疗法取得了有限的成功.
研究的目的:
- 审查AD中的线粒体功能障碍及其对突触功能的影响.
- 探索冬眠衍生的线粒体机制在阿尔茨海默病治疗中的潜力.
- 提出新的双重准策略,以促进阿尔茨海默病患者的线粒体健康.
主要方法:
- 对AD中线粒体功能障碍现有文献的综述.
- 对小鼠冬眠和每日的线粒体调节的分析.
- 基于冬眠衍生机制的潜在治疗策略的讨论.
主要成果:
- 线粒体功能障碍在阿尔茨海默氏病中显著导致突触损伤.
- 冬眠的动物表现出独特的线粒体适应来管理能量和防止氧化损伤.
- 受冬眠启发的策略为AD治疗提供了一种新的方法.
结论:
- 来自冬眠的线粒体机制,针对ATP生产和反应性氧物种 (ROS) 途径,对阿尔茨海默病有希望.
- 双线粒体向可以增强突触可塑性和功能.
- 对这些机制的进一步研究可能会导致更有效的阿尔茨海默病疗法.
相关概念视频
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
Electron Transport Chain: Complex I and II
13.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.4K
Mitochondria
12.7K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
12.7K


